A combination of humanized anti-CD19 and anti-B-cell maturation antigen chimeric antigen receptor T-cells has shown activity in patients with...
Myeloma NZ
Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBorD with or without thalidomide-based consolidation: a retrospective multi-centre analysis of real-world data
Bortezomib in combination with cyclophosphamide and dexamethasone (CyBorD, is a well-established frontline chemotherapy regimen for patients with...
Government urged to expand Pharmac’s drug budget after barrage of emotional pleas from sufferers
This story was originally published on Stuff "Why does New Zealand need to reinvent the wheel?" Posed by National MP Maggie Barry, that was the...
Health Select Committee hears pleas from survivors and sufferers
This story was originally published on RNZ Politicians heard emotional pleas today from cancer survivors, people with disabilities and health...
Blood cancer patient advocacy group presents to Health Select Committee to fund life-extending treatments
Dr Ken Romeril, chief executive, Myeloma New Zealand, is appearing today before the Health Select Committee in support of their submission asking...
Overview of the Report – Assoc Professor Richard Milne
Click below to view presentation
The Way Forward – Dr David Simpson
Click below to view presentation
Key Treatment Priorities – Dr Ken Romeril
Click below to view presentation
Patients’ Perspective – Joy Wilkie
Kia ora koutou, kō Ngati Tarawhai me Ngaiterangi ngā iwi, kō Joy Wilkie ahau, Tēnā koutou katoa It’s great to be alive and here today. Thanks Dr...
Patients’ Perspective – Paul Crosbie
Click below to view presentation
Ken Romeril speech at the Burden of Disease launch 26 June, 2019
Welcome and introduction of Dr Liz Craig. No mai, haere mai: Dr Craig, Members of Parliament, colleagues, health sector professionals, patients and...
Dr. Nadeem on Individualizing Therapy in Multiple Myeloma
Omar Nadeem, MD, a physician at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School, discusses individualizing...